Disease landscape
Ovarian Cancer
The GAP analysis revealed relatively modest limitations in access to ovarian cancer treatment and diagnosis in the Visegrad Group (V4) countries. The results are however highly variable across individual countries: Poland scored as high as 79 points, Slovakia and the Czech Republic achieved 63–67 points, while Hungary scored 51 points. The main factor lowering the score in all countries except Poland is limited access to authorised medicines in the V4 region, which translates into a suboptimal proportion of patients using PARP inhibitors.
Cross-Country
General GAP for Ovarian Cancer
Compliance with guidelines
Three medicines used in the treatment of ovarian cancer were recommended in clinical practice guidelines. Two of them are available to patients in each of the V4 countries, while in Poland are all three medicines publicly reimbursed, which translates into a 100% guideline compliance score in Poland and 67% in the other countries.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
PARP inhibitors
Drug access
Number of patients treated (2024)8
*Estimates for Hungary from 2023
Drug access
Population treated (%)
Main issues
- The average time to reimbursement for ovarian cancer drugs in the V4 countries is 5.2 years. The difference between the shortest and the longest mean time to reimbursement among the coutriess is over 2.6 years.
- In Poland, over 90% of ovarian cancer patients who are potentially eligible for PARP inhibitors were actually treated with one of these medicines, whereas in the other V4 countries this proportion was approximately 40–50%.
- DALY (disability adjusted life-years) burden in most V4 countries is far above the European Union average. The only exception is Slovakia with the most recent DALY burden being exactly at the average EU level.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).